Mankind Pharma Ltd (MANKIND)

Mankind Pharma Applauds Government's Healthcare Budget - 23 Jul, 2024

Mankind Pharma COO and FICCI Pharma Committee Chairman, Arjun Juneja, has praised the Indian government's 2024-25 budget for its commitment to healthcare growth and development. He highlights the allocation for long-term R&D financing in pharma, recognition of the sector as a sunrise industry, and exemption of customs duties on three additional cancer medications as particularly encouraging. The initiatives have the potential to transform India's healthcare landscape, making it more resilient, accessible, and aligned with our vision of a healthier nation.

Mankind Pharma Competes for BSV Group Acquisition - 18 Jul, 2024

Mankind Pharma is competing with a consortium led by EQT and ADIA to acquire BSV Group from Advent International for approximately Rs 14,000 crore ($1.67 billion).

Mankind Pharma Sees Increase in FII/FPI Holding; Advocates for Barcodes on Medicines - 17 Jul, 2024

Mankind Pharma witnesses an increase in FII/FPI holding and a 14% YoY revenue growth in Q1FY25. The company's CEO also advocates for the mandatory use of barcodes and QR codes on medicines.

Mankind Pharma's High P/E Ratio Raises Concerns - 12 Jul, 2024

Mankind Pharma's P/E ratio of 44.3x is higher than most Indian companies, despite an inferior earnings outlook and slower growth predictions. Shareholders' investments are at risk, and potential investors may pay an excessive premium.

Capital Group Affiliate Sells Stake in Mankind Pharma - 10 Jul, 2024

Capital Group affiliate Hema CIPEF has sold a total of 0.9% stake in Mankind Pharma worth Rs 771 crore through block deals managed by Kotak Securities and IIFL Securities. The buyers included marquee investors such as Citigroup, Copthall Mauritius, Bofa Securities, Goldman Sachs, ICICI Pru MF, LIC MF, Morgan Stanley and others.

Hema CIPEF Likely to Sell Stake in Mankind Pharma - 09 Jul, 2024

US-based Capital Group's affiliate, Hema CIPEF, is set to sell a 0.9% stake in Mankind Pharma for Rs 762.6 crore through block deals. The issue price is set at Rs 2,061 per share, reflecting a 2% discount to the current market price.

Mankind Pharma Front-Runner to Buy Bharat Vaccines and Serums - 03 Jul, 2024

Mankind Pharma is reportedly leading the bid to acquire Bharat Vaccines and Serums from Advent International for around $1.7-2 billion, with an aggressive bid at the upper end of the deal size. The Delhi-based pharma company has equipped itself with adequate firepower to undertake the transaction without straining its balance sheet. Bharat Serums would supplement Mankind Pharma's own domestic pharma business.

Promoters of Mankind Pharma Ltd may sell shares for compliance with minimum public shareholding norms - 01 Jul, 2024

According to market analyst Prasad, promoters of Mankind Pharma Ltd may sell shares to comply with minimum public shareholding norms. The selling is not just linked to current bullish market conditions but also includes business expansion and debt reduction.

Mankind Pharma Ltd Falls for Fifth Straight Session - 25 Jun, 2024

Mankind Pharma Ltd's stock fell by 1.67% to Rs 2128.8 on the NSE, while the benchmark NIFTY rose around 0.6%. The company has gained around 0.68% in the last month and has a PE of 47.58 based on TTM earnings ending March 24.